natgillin/translations-raw huggingface dataset:
Imprida HCT 10 mg/160 mg/12,5 mg filmovertrukne tabletter amlodipin/valsartan/hydrochlorthiazid
Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Imprida HCT 10 mg/160 mg/12,5 mg filmovertrukne tabletter er svagt gule, ovale tabletter præget med ”NVR” på den ene side og ”VDL” på den anden side.
Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side.
Imprida HCT 10 mg/160 mg/25 mg filmovertrukne tabletter amlodipin/valsartan/hydrochlorthiazid
Imprida HCT 10 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Imprida HCT 10 mg/160 mg/25 mg filmovertrukne tabletter er brun-gule, ovale tabletter præget med ”NVR” på den ene side og ”VHL” på den anden side.
Imprida HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side.
Imprida HCT 10 mg/160 mg/25 mg filmovertrukne tabletter: Hver filmovertrukket tablet indeholder 10 mg amlodipin (som amlodipinbesylat), 160 mg valsartan og 25 mg hydrochlorthiazid.
Imprida HCT 10 mg/160 mg/25 mg film-coated tablets: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan, and 25 mg hydrochlorothiazide.
Imprida HCT 10 mg/320 mg/25 mg filmovertrukne tabletter amlodipin/valsartan/hydrochlorthiazid
Imprida HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Imprida HCT 10 mg/320 mg/25 mg filmovertrukne tabletter er brun-gule, ovale tabletter præget med ”NVR” på den ene side og ”VFL” på den anden side.
Imprida HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side.
Imprida HCT 10 mg/320 mg/25 mg filmovertrukne tabletter: Hver filmovertrukket tablet indeholder 10 mg amlodipin (som amlodipinbesylat), 320 mg valsartan og 25 mg hydrochlorthiazid.
Imprida HCT 10 mg/320 mg/25 mg film-coated tablets: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 320 mg valsartan, and 25 mg hydrochlorothiazide.
Imprida HCT 5 mg/160 mg/12,5 mg filmovertrukne tabletter amlodipin/valsartan/hydrochlorthiazid
Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Imprida HCT 5 mg/160 mg/12,5 mg filmovertrukne tabletter er hvide, ovale tabletter præget med ”NVR” på den ene side og ”VCL” på den anden side.
Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets are white, oval tablets with “NVR” on one side and “VCL” on the other side.
Imprida HCT 5 mg/160 mg/12,5 mg filmovertrukne tabletter: Hver filmovertrukket tablet indeholder 5 mg amlodipin (som amlodipinbesylat), 160 mg valsartan og 12,5 mg hydrochlorthiazid.
Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets: Each film-coated tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.
Imprida HCT 5 mg/160 mg/25 mg filmovertrukne tabletter amlodipin/valsartan/hydrochlorthiazid
Imprida HCT 5 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Imprida HCT 5 mg/160 mg/25 mg filmovertrukne tabletter er gule, ovale tabletter præget med ”NVR” på den ene side og ”VEL” på den anden side.
Imprida HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side.
Imprida HCT 5 mg/160 mg/25 mg filmovertrukne tabletter: Hver filmovertrukket tablet indeholder 5 mg amlodipin (som amlodipinbesylat), 160 mg valsartan og 25 mg hydrochlorthiazid.
Imprida HCT 5 mg/160 mg/25 mg film-coated tablets: Each film-coated tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.
Imprida HCT anvendes til behandling af essentiel hypertension (forhøjet blodtryk) hos voksne, hvis blodtryk allerede er tilstrækkeligt kontrolleret med en kombination af amlopidin, valsartan og hydrochlorthiazid. ‘Essentiel’ betyder, at hypertensionen ikke har nogen umiddelbar årsag.
Imprida HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide. ‘Essential’ means that the hypertension has no obvious cause.
Imprida HCT er kontraindiceret til patienter med hyperkalcæmi og bør kun anvendes efter korrektion af præ- eksisterende hyperkalcæmi.
Imprida HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia.
Imprida HCT frarådes i den tidlige periode af graviditeten og må ikke tages, hvis du er mere end 3 måneder henne i graviditeten, da det kan forårsage alvorlig skade på dit barn, hvis det tages på dette tidspunkt (se afsnittet om ”Graviditet og amning”).
Imprida HCT is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at this stage (see section “Pregnancy and breast- feeding”).
Imprida HCT frarådes i den tidlige periode af graviditeten og må ikke tages, når du er mere end
Imprida HCT is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Imprida HCT kan tages af patienter på 65 år og derover med samme dosis som for voksne patienter og på samme måde, som de allerede tager de tre stoffer, som kaldes amlodipin, valsartan og hydrochlorthiazid.
Imprida HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide.
Imprida HCT og ældre patienter (65 år og derover)
Imprida HCT and older people (age 65 years and older)
Imprida HCT’s sikkerhedsprofil, som er præsenteret herunder, er baseret på kliniske afprøvninger udført med Imprida HCT og de kendte sikkerhedsprofiler af de individuelle komponenter amlodipin, valsartan og hydrochlorthiazid.
The safety profile of Imprida HCT presented below is based on clinical studies performed with Imprida HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.
Imprida må ikke anvendes til patienter, der er overfølsomme (allergiske) over for amlodipin eller andre lægemidler i gruppen af "dihydropyridinderivater", valsartan eller andre af indholdsstofferne.
Imprida must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the ‘dihydropyridine derivatives’ class, to valsartan, or to any of the other ingredients.
Improvac anvendes som et alternativ til fysisk kastration (fjernelse af testiklerne) for at reducere tilstedeværelsen af disse forbindelser.
Improvac is used as an alternative to physical castration (removal of the testicles) to reduce the presence of these compounds.
Improvac anvendes til at mindske "ornelugten" i kødet fra hangrise.
Improvac is used to reduce ‘boar taint’ in the meat obtained from male pigs.
Improvac er et immunologisk lægemiddel, der virker som en vaccine (stimulerer immunsystemet til at producere antistoffer).
Improvac is an immunological product which has an action mode similar to that of a vaccine (stimulates the immune system to produce antibodies).
Improvac gives til unge hangrise i form af 2 doser med mindst 4 ugers mellemrum.
Improvac is given to young male pigs as two doses, with at least a 4 week interval.
Improvac indeholder også en adjuvans (et kemikalie, der er udledt af sukkerarten dextran).
Improvac also contains an adjuvant (a chemical derived from the sugar dextran).
Improvac injektionsvæske, opløsning
Improvac solution for injection
Improvac Injektionsvæske, opløsning til grise
Improvac, solution for injection for pigs
Improvac må ikke anvendes til sogrise eller til hangrise, der er beregnet til avl.
Improvac must not be used in female pigs or in male pigs intended for breeding.
Impulsivitet.
Disinhibition
Imrestor 15 mg injektionsvæske, opløsning til kvæg
Imrestor 15 mg solution for injection for cattle
Imrestor 15 mg injektionsvæske, opløsning til kvæg pegbovigrastim
Imrestor 15 mg solution for injection for cattle pegbovigrastim
Imumunkompromitterede patienter
Immunocompromised patients
Imvanex blev i undersøgelser påvist at være effektivt til at anspore produktion af antistoffer i et omfang, der forventes at yde beskyttelse mod kopper.
Imvanex was shown in studies to be effective at triggering the production of antibodies to a level expected to provide protection against smallpox.
Imvanex er blevet godkendt under "særlige omstændigheder".
Imvanex has been authorised under ‘exceptional circumstances’.
Imvanex fås som en injektionsvæske, suspension, til indgivelse under huden, helst i overarmen.
Imvanex is available as a suspension for injection under the skin, preferably in the upper arm.
Imvanex indeholder en modificeret form for vaccinia-virus, som ikke forårsager sygdom hos mennesker, og som ikke kan replikere i menneskeceller.
Imvanex contains a modified form of the vaccinia virus called vaccinia Ankara, which does not cause disease in humans and cannot replicate (reproduce) in human cells.
IMVANEX indeholder natrium
IMVANEX contains Sodium
IMVANEX injektionsvæske, suspension
IMVANEX suspension for injection
Imvanex levende modificeret vaccinia Ankara-virus
Imvanex live modified vaccinia Ankara virus
Imvanex vil derfor være til gavn for personer, der ikke kan gives vacciner indeholdende replikerende vira, såsom patienter med et svækket immunsystem.
Imvanex would therefore be beneficial for people who cannot be given vaccines containing replicating viruses, such as patients with a weakened immune system.
IMVANEXs sikkerhed er blevet vurderet i 18 kliniske studier, hvor 5028 Vaccinia-naive personer fik to doser 1 x 108 TCID50 med fire ugers mellemrum, mens 534 Vaccinia- og IMVANEX-eksponerede personer fik en enkelt booster-dosis.
The safety of IMVANEX has been assessed in 18 clinical trials in which 5,028 Vaccinia-naïve individuals received two doses 1 x 108 TCID50 four weeks apart while 534 Vaccinia- and IMVANEX-experienced individuals received a single booster dose.
IMVANEXs sikkerhed og virkning hos personer under 18 år er ikke klarlagt.
The safety and efficacy of IMVANEX in individuals below 18 years of age have not been established.
IMVANEX® injektionsvæske, suspension Koppevaccine
IMVANEX® suspension for injection Smallpox vaccine
imvastatin (bruges til at sænke kolesterol),
imvastatin (used to lower cholesterol),
imvastatin (medicin som bruges til at behandle højt kolesterol);
imvastatin (a medicine used to control high cholesterol levels);
imvastatin (medicin til at sænke kolesteroltallet), da dosis måske skal justeres.
imvastatin (a medicine used to lower cholesterol levels) since your dose may have to be adjusted;
imvastatin og lovastatin (kolesterolsænkende midler)
imvastatin, lovastatin (used to lower cholesterol);
imvastatin og lovastatin - til at sænke kolesterolindholdet i blodet. quetiapin – bruges til at behandle skizofreni, bipolar (manio-depressiv) lidelse og svær depression
imvastatin and lovastatin - for lowering blood cholesterol quetiapine – used to treat schizophrenia, bipolar disorder and major depressive disorder.
imvastatin og lovastatin - til at sænke kolesterolindholdet i blodet. quetiapin – bruges til at behandle skizofreni, bipolar (manio-depressiv) lidelse og svær depression
imvastatin and lovastatin – for lowering blood cholesterol quetiapine – used to treat schizophrenia, bipolar disorder and major depressive disorder.
imvastatin og muligvis også andre statiner (bruges til behandling af forhøjet kolesteroltal). medicin, som nedsætter mængden af mavesyre.
imvastatin and possibly other statins (used to treat high cholesterol levels). medicines that reduce stomach acid.
imvastatin, lovastatin (bruges til at sænke kolesterol i blodet);
imvastatin, lovastatin (used to lower blood cholesterol);
imvastatin, lovastatin (øget risiko for myopati herunder rabdomyolyse)
imvastatin, lovastatin (increased risk of myopathy including rhabdomyolysis)
imvastin eller lovastatin (medicin mod forhøjet kolesteroltal)
imvastatin or lovastatin (used to lower blood cholesterol)
IN
19.0
IN
NR
IN = ikke nået
NR = not reached
In ACTIVE-A was het percentage ernstige bloedingen groter in de clopidogrel + ASA groep dan in de placebo + ASA groep (6,7% versus 4,3%).
In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%).
In CAPRIE bedroeg de totale frequentie van alle bloedingen 9,3% bij patiënten die behandeld werden met clopidogrel of ASA.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
In CD-studie I , blev 299 TNF-antagonist-naive patienter randomiseret til en af fire behandlingsgrupper: placebo i uge 0 og 2, 160 mg Humira i uge 0 og 80 mg i uge 2, 80 mg i uge 0 og 40 mg i uge 2, og 40 mg i uge 0 og 20 mg i uge 2.
In CD Study I, 299 TNF-antagonist naive patients were randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and 80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2.
In CD-studie I blev 299 TNF-antagonist-naive patienter randomiseret til en af fire behandlingsgrupper: placebo i uge 0 og 2, 160 mg Humira i uge 0 og 80 mg i uge 2, 80 mg i uge 0 og 40 mg i uge 2, og 40 mg i uge 0 og 20 mg i uge 2.
In CD Study I, 299 TNF-antagonist naive patients were randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and 80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2.
In CHARISMA en één cohortstudie (Simon) werd alleen bij de slechte metabolisers een hoger aantal voorvallen opgetekend vergeleken met de snelle metabolisers.
In CHARISMA and one cohort study (Simon), an increased event rate was observed only in poor metabolisers when compared to extensive metabolisers.
In CLARITY is een algemene toename van bloedingen waargenomen in de groep met clopidogrel plus ASA versus de groep met placebo plus ASA.
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group .The incidence of major bleeding was similar between groups .
In COMMIT was de mate van niet-cerebrale ernstige bloedingen of cerebrale bloedingen laag en vergelijkbaar in beide groepen.
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups.
In CURE, CLARITY, ACTIVE-A en één van de cohortstudies (Trenk) werd geen hoger aantal voorvallen opgetekend op basis van de metaboliserstatus.
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.
In de CURE-studie werden 823 (6,6 %) patiënten gelijktijdig behandeld met een GPIIb/IIIa receptor antagonist.
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
In de gedrukte bijsluiter van het geneesmiddel moeten de naam en het adres van de fabrikant die verantwoordelijk is voor vrijgifte van de desbetreffende batch zijn opgenomen.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
In de langetermijn veiligheidsopvolging van deze studie kregen 26 patiënten waarbij de shunt nog aanwezig was op de leeftijd van 1 jaar, clopidogrel tot de leeftijd van 18 maanden.
In the long-term safety follow-up of this study, 26 patients with the shunt still in place at one year of age received clopidogrel up to 18 months of age.
In de literatuur zijn slechts beperkt gegevens beschikbaar over Aziatische populaties om de klinische implicatie van genotypering van deze CYP op de klinische uitkomsten te kunnen beoordelen.
From literature, limited data in Asian populations are available to assess the clinical implication of genotyping of this CYP on clinical outcome events.
In de “intention to treat” analyse werden 939 complicaties waargenomen in de clopidogrel-groep en 1020 complicaties met ASA (een relatieve risicoreductie (RRR) van 8,7 %, [95 % CI: 0,2-16,4 %]; p = 0,045), hetgeen wil zeggen dat, voor elke 1000 patiënten die 2 jaar behandeld worden, er tot 10 [CI: 0 tot 20] patiënten extra gespaard zullen blijven van een nieuwe ischemischeaanval.
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
In det fase III-studie havde patienter der fik VELCADE subkutant sammenlignet med som intravenøs administration en 13 % lavere samlet forekomst af bivirkninger i forbindelse med behandlingen i form af grad 3 toksicitet, og en 5 % lavere forekomst af seponering af behandling med VELCADE.
In the Phase III study patients who received VELCADE subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were Grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of VELCADE.
In dierstudies bleek clopidogrel de fertiliteit niet te beïnvloeden.
Clopidogrel was not shown to alter fertility in animal studies.
In een gerandomiseerde, dubbelblinde studie met parallele groepen (CLARINET), werden 906 pediatrische patiënten (pasgeborenen en zuigelingen) met cyanotisch congenitaal hartlijden die behandeld werden met een palliatieve arterio-pulmonale shunt, gerandomiseerd naar clopidogrel 0,2 mg/kg (n=467) of placebo (n=439) in combinatie met de gelijktijdige standaardbehandeling tot het tijdstip van tweede fase chirurgie.
In a randomised, double-blind, parallel-group study (CLARINET), 906 paediatric patients (neonates and infants) with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt were randomised to receive clopidogrel 0.2 mg/kg (n=467) or placebo (n=439) along with concomitant background therapy up to the time of second stage surgery.
In een klein aantal gevallen werden ook bloedingen in het oog, het hoofd, de longen of de gewrichten gemeld.
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.
In een studie met geleidelijke dosisstijgingen bij 86 pasgeborenen of zuigelingen tot 24 maanden met een risico op trombose (PICOLO), werd clopidogrel geëvalueerd bij opeenvolgende doses van 0,01, 0,1 en 0,2 mg/kg bij pasgeborenen en zuigelingen en 0,15 mg/kg enkel bij pasgeborenen.
In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates.
In een vergelijkende biologische beschikbaarheidsstudie bij volwassenen, toonde de bereide oplossing van clopidogrel een vergelijkbare mate en een iets hogere snelheid van absorptie van de voornaamste circulerende (inactieve) metaboliet in vergelijking met de goedgekeurde tablet.
In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the authorised tablet.
In ovo
log10 PFU
In ovo
use
In ovo:
For in ovo route:
In ovo:
In-ovo:
In totaal kreeg 23,0% van de patiënten anti-aritmica, 52,1% bètablokkers, 54,6% ACE-remmers en 25,4% statines.
A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.
In vitro -studier viser, at bortezomib er en svag hæmmer af CYP-isozymer 1A2, 2C9, 2C19, 2D6 og 3A4.
In vitro studies indicate that bortezomib is a weak inhibitor of the cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4.
In vitro aktivitet over for følgende patogener er vist, men den kliniske betydning er ukendt: Curvularia spp. og Sporothrix spp.
In vitro activity against the following pathogens has been shown, but the clinical significance is unknown: Curvularia spp. and Sporothrix spp.
In vitro aktivitet over for kliniske isolater er set over for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp. og Histoplasma capsulatum, hvor de fleste stammer bliver hæmmet af voriconazolkoncentrationer i området fra 0,05 til 2 g/ml.
In vitro activity against clinical isolates has been observed for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., and Histoplasma capsulatum, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 µg/ml.
In vitro aktivitet over for kliniske isolater er set over for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp. og Histoplasma capsulatum, hvor de fleste stammer bliver hæmmet af voriconazolkoncentrationer i området fra 0,05 til 2 g/ml.
In vitro activity against clinical isolates has been observed for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., and Histoplasma capsulatum, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 μg/ml.
In vitro antagonisme af anti- hiv-aktivitet mellem stavudin og zidovudin kan resultere i nedsat virkning af begge lægemidler.
In vitro antagonism of anti-HIV activity between stavudine and zidovudine could result in decreased efficacy of both drugs.
In vitro antagonisme af anti-hiv- aktivitet mellem stavudin og zidovudin kan resultere i nedsat virkning af begge lægemidler.
In vitro antagonism of anti-HIV activity between stavudine and zidovudine could result in decreased efficacy of both drugs.
In vitro apixaban forsøg viste ingen hæmmende effekt på aktiviteten af CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 eller CYP3A4 (IC50 > 45 µM) og svag hæmmende effekt på aktiviteten af CYP2C19 (IC50 > 20 µM) ved koncentrationer, der er signifikant højere end maksimal plasmakoncentration observeret hos patienter.
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 M) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 M) at concentrations that are significantly greater than peak plasma concentrations observed in patients.
In vitro bindes fondaparinux med høj affinitet og specifikt til antitrombinprotein med en dosisafhængig plasmakoncentrationsbinding (98,6- 97,0 % i koncentrationsintervallet fra 0,5 til 2 mg/l).
In vitro, fondaparinux is highly and specifically bound to antithrombin protein with a dose-dependant plasma concentration binding (98.6% to 97.0% in the concentration range from 0.5 to 2 mg/l).
In vitro bindes fondaparinux med høj affinitet og specifikt til ATIII-protein, [hvilket giver en plasmakoncentrationsbinding] (98,6-97,0 % i koncentrationsintervallet fra 0,5 til 2 mg/l).
In vitro, fondaparinux is highly and specifically bound to antithrombin protein with a dose-dependant plasma concentration binding (98.6% to 97.0% in the concentration range from 0.5 to 2 mg/l).
In vitro binding af emtricitabin til humane plasmaproteiner var < 4% og uafhængig af koncentrationen over området på 0,02-200 µg/ml.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/ml.
In vitro blev CYP3A4 påvist at være det enzym, som primært var ansvarligt for metabolisme af olaparib (se pkt.
In vitro, CYP3A4 was shown to be the enzyme primarily responsible for the metabolism of olaparib (see section 4.5).
In vitro blev der set langsom metabolisk omsætning af velpatasvir via CYP2B6, CYP2C8 og CYP3A4.
In vitro, slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed.
In vitro data indikerer, at ledipasvir kan være en svag inducer af metaboliserende enzymer, såsom CYP3A4, CYP2C og UGT1A1.
In vitro data indicate that ledipasvir may be a weak inducer of metabolising enzymes such as CYP3A4, CYP2C and UGT1A1.